DiLeo M, Oglesby S, Leung CH, Pauken KE, et al. Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele. Cancer 2026;132:e70262.
PMID: 41563778